California Bill Aims to Clear Logjam for Psychedelic Treatment Research

California Bill Aims to Clear Logjam for Psychedelic Treatment Research

California lawmakers are on the brink of resolving a significant bottleneck that has hindered numerous studies related to addiction treatment, psychedelics, and other federally restricted drugs. The Research Advisory Panel of California, responsible for vetting studies involving cannabis, hallucinogens, and treatments for controlled substance abuse, has been a pivotal obstacle for researchers in California.

Click here to find ketamine clinics closest to you as well as other psychedelic therapies in your area.

The panel’s operations came to a halt due to concerns regarding compliance with the Bagley-Keene Act, a state law mandating open meetings. This hiatus has led to a backlog of 42 new studies and 28 amendments awaiting approval, causing frustration among researchers like Ziva Cooper from the UCLA Center for Cannabis and Cannabinoids.

Lots of Frustrations

Cooper, who submitted studies on cannabis health risks for different age groups and the potential of cannabis and psilocybin for pain relief and addiction treatment, has been at a standstill due to the panel’s inactivity. The impasse not only affects ongoing research but also jeopardizes future studies and funding, prompting concerns about losing talented researchers to other states.

New: Interested in Being Part of a Psychedelics-Focused Clinical Trial? Sign Up Here

Assembly Bill 2841, proposed by Assemblymember Marie Waldron, offers a solution to reactivate stalled research by allowing closed sessions for sensitive studies. While supported by organizations like Veterans Exploring Treatment Solutions, some researchers advocate for abolishing the panel altogether, citing delays, unnecessary expenditures, and missed opportunities for Californians to participate in cutting-edge trials.

Ready to explore a new horizon in mental health? Try out the beta version of HealingChat, HealingMaps AI chatbot that takes all our vetted content, clinics and retreats to answer all your questions in a safe environment. Try the beta version now!

The bill’s impact on addiction research, the need for streamlining approval processes, and the debate over the panel’s efficacy underscore the urgency of addressing the research impasse in California. As the state navigates the complexities of drug research regulation, the outcome of AB 2841 holds the key to unlocking the potential of groundbreaking studies in addiction treatment and psychedelics.

For more details, check out the LA Times.

Healing Maps Editorial Staff

Healing Maps Editorial Staff

View all posts by Healing Maps Editorial Staff

The Healing Maps Editorial Team has decades of experience across all facets of the psychedelic industry. From assessing studies and clinic research, to working with clinician's and clinics, we help provide data-backed information to psychedelic-curious individuals across the globe.

Related Posts

Leave a Reply

Your email address will not be published. Required fields are marked *

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Explore Psychedelic Therapy Regions